The higher total tau levels in AD patients compared to NABD patients are probably not a result solely of the disease’s duration and ongoing neurodegeneration, as the time between disease onset and of assessing the CSF and neural autoantibodies and neurodegeneration markers did not differ between groups. This evidence concerns the gene MAPT and Alzheimer disease.